Cypherpunk Technologies hosts a conference call for investors and analysts today, May 20, 2026, at 9:30 AM ET. The session addresses first-quarter 2026 financial results previously reported on May 14, 2026.
The company recorded a net loss of $77.2 million for the quarter. Unrealized losses on significant Zcash (ZEC) holdings primarily caused this financial deficit.
Management will detail a dual strategy involving a digital asset treasury and cancer therapy development through its subsidiary, Leap Therapeutics. The FDA granted Fast Track designation to the subsidiary's drug candidate, sirexatamab, in May 2026. Cypherpunk also recently increased its total investment in Zcash.